Literature DB >> 22211134

Peek before you treat? Is it a fantasy or reality?

Jaffer A Ajani1, Pamela B Mangu, Harold J Burstein.   

Abstract

Empirical approaches brought about use of the once-promising CSRA. However, oncologists now know that most cancers are highly complex, and that even the same tumor type can harbor differing genetic abnormalities.

Entities:  

Year:  2011        PMID： 22211134      PMCID： PMC3170070          DOI： 10.1200/JOP.2011.000405

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  9 in total

1.  Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience.

Authors:  Bin Wu; Jin-Shui Zhu; Yi Zhang; Wei-Ming Shen; Qiang Zhang
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

2.  Through the glass lightly.

Authors:  B Vogelstein; K W Kinzler
Journal:  Science       Date:  1995-03-17       Impact factor: 47.728

3.  In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.

Authors:  Selma Ugurel; Dirk Schadendorf; Claudia Pföhler; Karsten Neuber; Adina Thoelke; Jens Ulrich; Axel Hauschild; Konstanze Spieth; Martin Kaatz; Werner Rittgen; Stefan Delorme; Wolfgang Tilgen; Uwe Reinhold
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

4.  Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.

Authors:  H Gallion; W A Christopherson; R L Coleman; L DeMars; T Herzog; S Hosford; H Schellhas; A Wells; B-U Sevin
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

5.  American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.

Authors:  Harold J Burstein; Pamela B Mangu; Mark R Somerfield; Deborah Schrag; David Samson; Lawrence Holt; Debra Zelman; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

6.  Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer.

Authors:  Won Deok Joo; Ji Young Lee; Jong Hyeok Kim; Hang Jo Yoo; Hyun Jin Roh; Jeong-Yeol Park; Dae-Yeon Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

7.  American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

Authors:  Deborah Schrag; Harinder S Garewal; Harold J Burstein; David J Samson; Daniel D Von Hoff; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

8.  A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.

Authors:  Ian A Cree; Christian M Kurbacher; Alan Lamont; Andrew C Hindley; Sharon Love
Journal:  Anticancer Drugs       Date:  2007-10       Impact factor: 2.248

9.  In vivo genome editing restores haemostasis in a mouse model of haemophilia.

Authors:  Hojun Li; Virginia Haurigot; Yannick Doyon; Tianjian Li; Sunnie Y Wong; Anand S Bhagwat; Nirav Malani; Xavier M Anguela; Rajiv Sharma; Lacramiora Ivanciu; Samuel L Murphy; Jonathan D Finn; Fayaz R Khazi; Shangzhen Zhou; David E Paschon; Edward J Rebar; Frederic D Bushman; Philip D Gregory; Michael C Holmes; Katherine A High
Journal:  Nature       Date:  2011-06-26       Impact factor: 49.962
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.